Print

Plasma VEGF as a Marker of Therapy in Breast Cancer Patients.

Issue: Vol.10, No.3 - July 2011

« Back to Articles

Article Type: Manuscript

Download PDF Version »

  1. Dr Lakshmi Krishnamoorthy
    Associate Professor & In charge HOD Dept.of Biochemistry
    Kidwai Memorial Institute of Oncology,

Introduction: Angiogenesis, the process leading to the formation of new blood vessels from a preexisting vascular network, is necessary for tumor growth, invasion, and
metastasis. Vascular endothelial growth factor (VEGF) is one of the most potent angiogenic cytokines. Since blood biomarkers are minimally invasive, relatively easy to evaluate,we investigated the prognostic significance of plasma VEGF in Breast cancer patients.

Methods: Preoperative plasma VEGF levels were determined by enzyme-linked immunosorbant assay in 80 women with breast cancer and in 80 normal female controls

Results: There was a significant (P<0.001) increase in plasma VEGF level in breast cancer patients (Mean± SD 136.22±9.95) compared with controls(61.88±6.19). Our
study showed that increased plasma VEGF levels were significantly associated with menopausal status, clinical stage of disease and hormone receptor status.

Conclusion: Since the increased plasma VEGF levels were associated with menopausal status, clinical stage of disease and hormone receptor status, it can be used a possible surrogate pharmacodynamic marker for determining the optimal biological dose of antibody drugs.

Download PDF Version »

Favourites   Share / Bookmark

Related Articles

Also In This Issue

« Back to Articles